PMHNP Scope of Practice for ADHD in Georgia

If you’re a psychiatrist or psychiatric nurse practitioner considering telehealth ADHD care, you’re probably asking: Can I legally prescribe Adderall and other stimulants through video visits? What about state-specific rules? Will the federal telehealth flexibilities expire?

The short answer: Yes, you can prescribe ADHD medications via telehealth through the end of 2026 under current federal rules, but your state’s regulations around scope of practice and prescribing create important variations you need to understand.

Let’s cut through the confusion with what actually matters for your practice.

The Federal Landscape: You’re Good Through 2026 (With Changes Coming)

Here’s the reality: The DEA and HHS just extended telehealth prescribing flexibilities for controlled substances through December 31, 2026. This is the fourth extension since the COVID public health emergency ended, and it means you can continue prescribing Schedule II stimulants like Adderall, Vyvanse, and Ritalin after a video evaluation without any initial in-person exam.

The catch? This is temporary. The DEA is finalizing permanent rules that will likely require providers to obtain a Telemedicine Special Registration to continue this practice beyond 2026. These new rules will include safeguards like mandatory nationwide PDMP checks and strict patient identity verification, but they’re designed to preserve telehealth access while preventing abuse.

What You Need to Know About the Ryan Haight Act

Technically, the Ryan Haight Act still requires an in-person exam before prescribing controlled substances. But the federal government has waived this requirement continuously since March 2020, and the latest extension runs through 2026. The DEA is working on permanent regulations that will replace the waiver with a new framework—likely creating a special DEA registration category for telehealth prescribers.

Bottom line for your practice: Keep prescribing via telehealth using proper clinical judgment and documentation. Stay alert for DEA announcements about the special registration process (expected to launch before the 2026 deadline), and plan to complete whatever new requirements emerge. The government has signaled it won’t pull the rug out suddenly—they understand millions of patients rely on tele-psychiatry.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Rules: Where Geography Really Matters

Federal law sets the floor, but your state determines what you can actually do. Here’s what matters in the six states with the largest psychiatric patient populations:

California: Telehealth-Friendly with NP Independence Coming

California doesn’t require an in-person exam for prescribing—telehealth evaluations explicitly meet the legal standard. You can diagnose ADHD and prescribe stimulants via video as long as your clinical assessment is thorough.

For Psychiatrists: Full prescribing authority via telehealth. Just ensure you check the CURES PDMP database before the initial prescription and every 4 months for ongoing stimulant therapy (this is mandatory).

For PMHNPs: California is transitioning to full practice authority for experienced NPs. By 2026, NPs with 3 years or 4,600 hours of collaborative practice can practice independently—including prescribing stimulants without physician oversight. New graduates still need supervising agreements initially, but the trajectory is clear: California wants autonomous NP practice.

Licensing: You need a California medical or nursing license. CA isn’t part of the Interstate Medical Licensure Compact, so out-of-state providers must go through the full licensing process (which can take months).

Texas: Physicians Only for Stimulants

Texas allows telehealth mental health care but has a critical restriction: Nurse practitioners and physician assistants cannot prescribe Schedule II controlled substances in outpatient settings. Period. The only exceptions are hospital inpatient orders, hospice care, or ER emergency medication orders.

For Psychiatrists: You have full authority to prescribe ADHD medications via telehealth. Texas is part of the Interstate Medical Licensure Compact, so getting licensed is streamlined if you’re already licensed in another compact state.

For PMHNPs: You can evaluate and manage ADHD patients, but a physician must write the stimulant prescription. If you’re building a telehealth practice in Texas, you’ll need physician collaboration specifically for the prescribing component.

The Practical Reality: Texas telehealth ADHD care essentially requires psychiatrists (MD/DO). Platforms serving Texas patients typically use Texas-licensed psychiatrists or have formal physician oversight arrangements for their NP providers.

Florida: Explicit Permission for Psychiatric Telehealth

Florida created a specific carve-out in its telehealth law: providers can prescribe Schedule II controlled substances via telehealth for ‘treatment of a psychiatric disorder.’ ADHD explicitly qualifies.

For Psychiatrists: You can prescribe stimulants via telehealth without any in-person visit. Florida also offers an out-of-state telehealth provider registration—if you’re licensed in another state with a clean record, you can register with Florida’s Department of Health to treat Florida patients via telehealth (including prescribing ADHD meds) without getting a full Florida license.

For PMHNPs: Florida requires PMHNPs to work under a protocol agreement with a supervising psychiatrist. However, psychiatric nurses are exempt from the general 7-day limit on Schedule II prescriptions that applies to other NPs—you can prescribe full monthly refills. For treating minors, the law requires consultation with a pediatrician or psychiatrist.

Critical Requirement: You must check Florida’s E-FORCSE PDMP before prescribing controlled substances for patients age 16 and older. This is mandatory, not optional.

New York: Recently Aligned with Federal Rules

New York updated its regulations in May 2025 to explicitly allow controlled substance prescribing via telehealth consistent with federal law. Previously, state regulation mirrored the Ryan Haight Act’s in-person requirement, but NY removed this barrier.

For Psychiatrists: Full telehealth prescribing authority. You must check the I-STOP PMP registry before every Schedule II stimulant prescription (this is strictly enforced), and all controlled substance prescriptions must be electronic.

For PMHNPs: After 3,600 hours of practice, NPs in New York can practice independently without a written collaborative agreement—including prescribing stimulants. This is essentially full practice authority for experienced psychiatric NPs.

Useful Detail: New York allows up to 90-day prescriptions for ADHD stimulants if you use code ‘B’ (for ADHD/minimal brain dysfunction) on the prescription. This can significantly reduce administrative burden for stable patients compared to monthly refills.

Licensing: You need a New York license (no compact or telehealth registration option). You’ll also need an NYS controlled substance license number from the Bureau of Narcotic Enforcement in addition to your DEA registration.

Pennsylvania: Collaboration Required for NPs

Pennsylvania permits telehealth prescribing without state-imposed barriers beyond federal law. The medical boards confirm that provider-patient relationships can be established via telemedicine and prescribing is acceptable if the standard of care is met.

For Psychiatrists: Full authority. PA joined the Interstate Medical Licensure Compact in 2022, making it easier for out-of-state psychiatrists to get licensed. You must check the PA PDMP before the initial controlled substance prescription for any new patient.

For PMHNPs: You need a collaborative agreement with a physician. More importantly, PA law limits CRNPs to 30-day supplies of Schedule II controlled substances, with any continuation beyond 30 days requiring physician approval. Practically, this means your supervising psychiatrist needs to review cases before refills—monthly oversight is built into the regulation.

E-Prescribing: Pennsylvania mandated electronic prescribing for controlled substances in 2019. You’ll need EPCS-enabled technology to treat PA patients.

Illinois: Two-Tier System for NPs

Illinois allows broad telehealth practice and doesn’t impose state barriers to controlled substance prescribing. You’ll need an Illinois Controlled Substance License in addition to your professional license and DEA registration.

For Psychiatrists: Full prescribing authority via telehealth. Illinois is part of the IMLC for expedited licensing.

For PMHNPs: Illinois has a two-tier system. Under collaboration (standard NP practice), you can prescribe a 30-day supply of Schedule II stimulants, but any continuation requires physician approval, and your collaborating physician must review your Schedule II prescribing monthly.

However, Illinois offers Full Practice Authority for APRNs who complete 4,000 hours of practice under collaboration plus 250 hours of continuing education. Once you achieve FPA status, you can prescribe stimulants independently without physician consultation—the consultation requirement only applies to opioid narcotics and benzodiazepines, not stimulants.

Bottom Line: Experienced Illinois PMHNPs can operate independently for ADHD care. Newer NPs need physician oversight with the 30-day limit.

Key State Differences at a Glance

The Economics: Why Join a Platform vs DIY Marketing

Here’s the uncomfortable truth about building a telehealth ADHD practice on your own: patient acquisition is expensive and uncertain.

The Real Cost of DIY Patient Acquisition

When providers tell me they want to ‘market themselves’ for telehealth, I ask: Do you have $3,000–5,000 per month to invest for 6–12 months before seeing results?

Reality check on acquisition costs:

• SEO takes 6–12 months of consistent investment (content, technical optimization, link building) before you rank for competitive terms like ‘ADHD psychiatrist near me’ or ‘online ADHD doctor.’ You’re competing against established telehealth companies and directory sites with massive domain authority.

• Google Ads for mental health keywords run $15–40+ per click. Most clicks don’t convert to booked patients. Factor in click fraud, tire-kickers, and patients who ghost after the first call, and your cost per booked patient through PPC is typically $200–400+.

• Directory listings like Psychology Today charge monthly fees ($30+) and you’re competing with hundreds of other providers on the same page. Zocdoc charges per booking ($35–100+ depending on specialty) plus monthly subscription fees. The costs add up fast, and there’s no guarantee of patient quality or insurance fit.

• True all-in cost: When you factor in agency/consultant fees, ad spend testing, staff time to handle and qualify leads, no-show rates from cold leads, failed campaigns, and opportunity cost of your time—you’re realistically spending $200–500+ per acquired psychiatric patient, if your marketing works.

And here’s the kicker: most solo practitioners don’t have the expertise or the patience for this. Marketing is a full-time skill. You went to medical school to treat patients, not optimize Google Ads campaigns.

The Platform Model: Pay Only for Results

Compare that DIY gamble to a platform model like Klarity Health: you pay a standard listing fee per new patient lead—essentially paying only when a pre-qualified patient books with you.

What you get:

• No upfront marketing spend or monthly subscription gambling
• Pre-qualified patients already matched to your specialty, availability, and whether you take their insurance
• No wasted ad spend on clicks that don’t convert—you only pay when someone actually books
• Built-in telehealth infrastructure (no separate platform costs for video, EHR, e-prescribing)
• Both insurance and cash-pay patient flow, so you’re not limited to one model
• You control your schedule—set your availability and only see patients when you want

The economic equation is simple: Instead of spending thousands per month with uncertain results, you have guaranteed ROI. You pay for a patient, you see the patient, you get paid for the visit. Every appointment covers its acquisition cost and generates profit.

This is especially valuable for providers starting out or scaling from part-time to full-time telehealth. You eliminate the risk entirely while building your practice.

Compliance Essentials: What You Actually Need to Do

Regardless of which state you practice in, here are the non-negotiables:

1. PDMP Checks Are Mandatory (State-Specific Requirements)

Every state now requires or strongly recommends checking the Prescription Drug Monitoring Program before prescribing controlled substances. For ADHD stimulants:

• California: Check CURES initially and every 4 months
• New York: Check I-STOP registry before every stimulant prescription
• Florida: Check E-FORCSE before prescribing for patients 16+
• Pennsylvania, Illinois, Texas: Check at minimum for initial prescription; many providers check every time as best practice

Document that you reviewed the PDMP in your clinical notes. This isn’t just regulatory compliance—it’s essential for identifying patients who might be obtaining stimulants from multiple providers.

2. Electronic Prescribing Is Required

Most states now mandate e-prescribing for controlled substances. You need EPCS (Electronic Prescribing of Controlled Substances) technology that meets DEA requirements—two-factor authentication for the prescriber, secure transmission, etc.

If you’re joining a platform, ensure their EHR system supports EPCS in all states where you’ll practice. Setting this up yourself involves registering with e-prescribing networks and often paying per-prescription fees or monthly subscriptions.

3. Proper Clinical Documentation

The DEA has investigated telehealth companies for allegedly prescribing stimulants too liberally. Protect yourself with thorough documentation:

• Complete diagnostic assessment: Document DSM-5 criteria for ADHD, symptom history, functional impairment, ruling out other conditions
• Patient identity verification: Note how you confirmed the patient’s identity
• Informed consent: Document discussion of risks, benefits, alternatives, and patient agreement to telehealth treatment
• Treatment plan: Note why stimulant medication is appropriate, starting dose rationale, monitoring plan
• Follow-up protocols: Document how you’ll monitor response, side effects, and need for dosage adjustment

This isn’t just CYA—it’s the standard of care. If your documentation wouldn’t support an in-person prescription, it won’t support a telehealth one either.

4. State Licensure in Patient’s Location

You must be licensed where the patient is located at the time of the telehealth visit. A patient vacationing in Florida while you’re licensed only in New York? That’s practicing medicine in Florida without a license.

Most platforms handle this by restricting which patients you see based on your licenses. If you’re building multi-state capability, prioritize high-population states and consider:

• Interstate Medical Licensure Compact for physicians (25+ states participate)
• State-specific telehealth registrations where available (e.g., Florida)
• Full licenses in your target states (necessary for most NPs, since nurse compacts don’t cover practice authority)

What’s Coming: Preparing for the 2027 Rule Changes

The DEA’s permanent telemedicine rules will likely take effect in 2027. Based on their January 2025 announcements, here’s what to expect:

Telemedicine Special Registration: A new DEA registration category for providers who want to prescribe controlled substances via telehealth without an in-person exam. This will likely involve:

• Additional application and fee
• Mandatory participation in a national PDMP check system
• Stricter patient identity verification requirements
• Possible audit requirements or reporting obligations

Established Patient Exemption: If you’ve seen a patient in person at least once (or another provider in your practice has), the new telemedicine rules won’t apply to ongoing care. This matters for hybrid practices.

30-Day Supply Provisions: The DEA may implement tiered rules—potentially allowing a 30-day initial supply via telehealth without special registration, but requiring either the special registration or an in-person visit for continuation.

Platform Registration: For the first time, the DEA will require telehealth platforms (not just individual providers) to register. This adds corporate-level oversight to prevent ‘pill mill’ operations.

What you should do now: Stay informed about DEA announcements, plan to obtain the special registration when it becomes available, and ensure any platform you join is preparing for compliance. The goal is continuity—don’t wait until December 2026 to figure this out.

Making Telehealth ADHD Care Work for Your Practice

The regulatory landscape for telehealth ADHD prescribing is actually more favorable than many providers realize. The federal government has committed to preserving access through 2026 and is working on permanent rules that maintain telehealth options with appropriate safeguards.

The real variations are state-level:

• Psychiatrists have full authority everywhere (with proper licensing)
• PMHNPs face different restrictions depending on state—from full independence in California and New York to physician-dependent prescribing in Texas

The key questions aren’t ‘Is this legal?’ (it is) but rather:

1. Which states are you licensed in?
2. If you’re an NP, what’s your scope in each state?
3. How will you handle patient acquisition cost-effectively?
4. Are you prepared for the administrative requirements (PDMP, e-prescribing, documentation)?

For most providers, joining an established telehealth platform solves the patient acquisition challenge, provides the necessary technology infrastructure, and handles compliance monitoring—allowing you to focus on what you do best: treating patients.

The demand for ADHD care continues to outstrip supply. Telehealth removes geographic barriers and increases your earning potential. The regulations support this—you just need to understand the rules in your specific situation.

Frequently Asked Questions

Can I prescribe Adderall during a first telehealth visit?

Yes, under current federal rules (through December 2026), you can prescribe Schedule II stimulants like Adderall after an initial video evaluation without requiring an in-person exam. You must conduct a thorough clinical assessment that meets the standard of care—essentially, the same diagnostic process you’d use in person. Document your evaluation carefully, check the state PDMP, and ensure the patient is located in a state where you’re licensed.

Do the Ryan Haight Act rules still apply?

Technically yes, but the in-person exam requirement has been waived continuously since March 2020 and is currently extended through December 31, 2026. The DEA is finalizing permanent rules that will likely create a special registration pathway for telehealth prescribers instead of requiring in-person visits. Once those rules take effect (expected 2027), you’ll need to comply with whatever new requirements they establish—but the goal is maintaining telehealth access, not eliminating it.

Which states allow PMHNPs to prescribe ADHD medications independently?

California (for experienced NPs by 2026), New York (after 3,600 practice hours), and Illinois (with Full Practice Authority certification after 4,000 hours plus additional training) allow PMHNPs to prescribe stimulants independently. Florida requires physician protocol supervision. Pennsylvania and Illinois (without FPA) require collaboration with 30-day prescription limits. Texas prohibits NPs from prescribing Schedule II controlled substances in outpatient settings entirely.

How often do I need to check the state PDMP?

It varies by state. New York requires checking before every Schedule II stimulant prescription. California requires an initial check and then every 4 months for ongoing therapy. Most other states require checking before the initial prescription and periodically thereafter. Best practice: check the PDMP for every new patient and any time you have concerns about potential misuse or doctor shopping. Document each review in your clinical notes.

Can I prescribe 90-day supplies of stimulants via telehealth?

In most states, controlled substance prescriptions are limited to 30-day supplies, but there are exceptions. New York explicitly allows up to 90-day prescriptions for ADHD stimulants if you designate code ‘B’ on the prescription. Some states may allow longer supplies for stable patients with documented treatment history. Check your state’s specific controlled substance regulations, and remember that nurse practitioners in Pennsylvania and Illinois (under collaboration) are limited to 30-day Schedule II prescriptions regardless of patient stability.

What happens if my patient is traveling to another state?

You can only prescribe when the patient is physically located in a state where you hold an active license. If a patient you normally treat in New York travels to California for two weeks, you cannot prescribe during that time unless you also have a California license. This is a common issue with telehealth—patients need to inform you of their location before each visit, and you should document where they’re located at the time of service.

Do I need malpractice insurance that covers telehealth?

Yes. Most malpractice policies now include telehealth coverage, but verify this explicitly with your carrier. Some policies require you to notify the insurer that you’re practicing via telehealth or may have restrictions on which states are covered. If you’re practicing in multiple states, ensure your coverage extends to all locations where you’re licensed. Platform-based providers should also confirm what liability coverage (if any) the platform provides.

What are the upcoming DEA Telemedicine Special Registration requirements?

While the DEA hasn’t published final rule text, their January 2025 announcements indicate the special registration will require: (1) an additional DEA application and fee, (2) participation in mandatory nationwide PDMP checking (the DEA plans to create a national PDMP data hub), (3) strict patient identity verification during audio-video consultations, and (4) compliance with specific record-keeping requirements. The registration will be available to individual practitioners and will authorize prescribing controlled substances via telehealth to new patients without in-person exams. Details should be released before the current extension expires in December 2026.

Can I use audio-only (phone) visits for ADHD medication management?

Generally, no. Federal telehealth rules for controlled substance prescribing require real-time, two-way interactive audio-video communication. Audio-only visits don’t meet the standard for establishing a patient relationship for controlled substance prescribing under DEA rules (the only exception has been for buprenorphine in specific circumstances). All states align with this federal requirement—you need video capability to prescribe stimulants via telehealth.

How do I handle patients who request specific medications or dosages?

The same way you would in person: exercise independent clinical judgment. The DEA has scrutinized telehealth companies for allegedly rubber-stamping patient requests for stimulants. Document your independent assessment, why the requested medication is or isn’t appropriate, and any discussions about alternatives. If a patient is demanding a specific stimulant at a specific dose and you don’t believe it’s clinically justified, you’re not obligated to prescribe it—and documenting that you declined based on clinical judgment protects you. Remember: the fact that it’s telehealth doesn’t change your professional obligations around appropriate prescribing.

Ready to Build Your Telehealth ADHD Practice?

The regulatory framework supports telehealth ADHD care. The patient demand is real. The question is whether you want to spend months and thousands of dollars figuring out marketing, licensing, technology, and compliance on your own—or join a platform that handles the infrastructure so you can focus on treating patients.

Klarity Health connects psychiatrists and psychiatric nurse practitioners with pre-qualified ADHD patients across multiple states. You set your schedule, we handle patient acquisition, credentialing support, and provide the telehealth technology and e-prescribing tools you need.

No upfront marketing costs. No monthly subscriptions. Just a straightforward model where you pay per patient appointment and we deliver qualified patients who match your availability and credentials.

Join Klarity’s Provider Network to learn more about practicing telehealth ADHD care with full regulatory compliance and none of the patient acquisition risk.

Sources and References

The following sources were consulted to ensure accuracy and regulatory compliance. All information reflects current law as of February 2026.

1. DEA & HHS Press Release – Extension of Telemedicine Flexibilities Through 2026 (January 2, 2026)
   https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html
   Official government announcement extending controlled substance telehealth prescribing through December 31, 2026.

2. Healthcare Dive – ‘DEA, HHS extend telehealth controlled substance prescribing flexibilities for fourth time’ (January 5, 2026)
   https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/
   Industry news analysis covering the extension details and implications.

3. DEA Press Release – ‘DEA Announces Three New Telemedicine Rules to Continue Open Access’ (January 16, 2025)
   https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access
   Official DEA announcement of proposed permanent telemedicine rules, including special registration requirements.

4. RxAgent – ‘Nurse Practitioner Prescriptive Authority by State: 2026 Guide’ (Updated December 28, 2025)
   https://rxagent.co/blog/np-prescribing-authority
   Comprehensive state-by-state analysis of NP prescribing authority with statutory references.

5. Texas Board of Nursing – APRN Practice FAQ
   https://www.bon.texas.gov/faqpracticeaprn.asp.html
   Official Texas regulatory guidance on nurse practitioner prescribing limitations for Schedule II controlled substances.

6. Florida Statutes §456.47 – Telehealth
   https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499/0456/Sections/0456.47.html
   Florida law establishing psychiatric disorder exception for Schedule II telehealth prescribing.

7. Florida Statutes §464.012 – Nursing Practice and Prescribing
   https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&StatuteYear=2017&URL=0400-0499/0464/Sections/0464.012.html
   Florida statutory provisions for APRN prescribing authority and psychiatric nurse exemptions.

8. New York State Department of Health – Guidance on Prescribing Controlled Substances via Telehealth (May 2025)
   https://www.ninthdistrict.org/home/2025/05/30/nysdoh-issues-guidance-on-prescribing-controlled-substances-via-telehealth
   Official New York State guidance aligning state regulations with federal telehealth flexibilities.

9. Pennsylvania Code Title 49, Chapter 21 – CRNP Prescriptive Authority
   https://www.pacodeandbulletin.gov/secure/pacode/data/049/chapter21/chap21toc.html
   Pennsylvania administrative code establishing 30-day limit for NP prescribing of Schedule II controlled substances.

10. Illinois Administrative Code Title 68, Part 1300 – Nurse Practice Act Rules
    https://www.ilga.gov/agencies/JCAR/EntirePart?titlepart=06801300
    Illinois regulations covering APRN collaborative agreements, Full Practice Authority, and Schedule II prescribing limitations.

11. Center for Connected Health Policy – State Telehealth Laws: Online Prescribing (Updated January 2026)
    https://www.cchpca.org/topic/online-prescribing/
    Policy analysis and state law compilation covering telehealth prescribing standards, including California Business & Professions Code citations.

All regulatory information verified against primary sources as of February 10, 2026. Providers should monitor DEA announcements for updates to permanent telemedicine rules expected before December 31, 2026.

Source:

• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,II%20to%20Schedule%20V%20drugs
• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,to%20hash%20out%20permanent%20regulations
• https://rxagent.co/blog/np-prescribing-authority#:~:text=Proposed%20DEA%20rules%20create%20a,for%20telemedicine%20prescribing
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://www.bon.texas.gov/faqpracticeaprn.asp.html#:~:text=there%20any%20settings%20other%20than,may%20prescribe%20Schedule%20II%20controlled
• https://www.ninthdistrict.org/home/2025/05/30/nysdoh-issues-guidance-on-prescribing-controlled-substances-via-telehealth#:~:text=as%20such%20terms%20are%20defined,the%20use%20of%20electronic%20prescribing
• https://www.pacodeandbulletin.gov/secure/pacode/data/049/chapter21/chap21toc.html#:~:text=,
• https://www.ilga.gov/agencies/JCAR/EntirePart?titlepart=06801300#:~:text=match%20at%20L5536%203,collaborating%20physician%20or%20podiatric%20physician
• https://rxagent.co/blog/np-prescribing-authority#:~:text=However%2C%20,3
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Prescribing%2C%20dispensing%2C%20or%20furnishing%20dangerous,the%20appropriate%20standard%20of%20care